Miragen Therapeutics to Report Second Quarter 2019 Financial Results and Host a Conference Call on August 7th
24 Julho 2019 - 9:00AM
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage
biopharmaceutical company developing proprietary RNA-targeted
therapies with a specific focus on microRNAs, will host a
conference call on Wednesday, August 7th, at 4:30 p.m. ET to
discuss its financial results for the second quarter and six months
ended June 30, 2019.
Participants may access the call by dialing 877-407-0789 in the
U.S. or 201-689-8563 outside the U.S. and providing the conference
ID number: 13692701. The call will also be webcast and can be
accessed from the Investors and Media section of the Company’s
website at www.miragen.com. A replay of this conference call
will be available on miRagen’s website approximately one hour after
the event.
About miRagen Therapeutics, Inc.miRagen
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
discovering and developing proprietary RNA-targeted therapies with
a specific focus on microRNAs and their role in diseases where
there is a high unmet medical need. miRagen has three clinical
stage product candidates, cobomarsen, remlarsen, and MRG-110.
miRagen’s clinical product candidate for the treatment of certain
cancers, cobomarsen, is an inhibitor of microRNA-155, which is
found at abnormally high levels in malignant cells of several blood
cancers. miRagen’s clinical product candidate for the treatment of
pathological fibrosis, remlarsen, is a replacement for microRNA-29,
which is found at abnormally low levels in a number of pathological
fibrotic conditions, including cutaneous, cardiac, renal, hepatic,
pulmonary and ocular fibrosis, as well as in systemic sclerosis.
MRG-110, an inhibitor of microRNA-92, is being developed under a
license and collaboration agreement with Servier for the treatment
of heart failure and other ischemic disease. In addition to these
programs, miRagen is developing a pipeline of preclinical product
candidates. The goal of miRagen’s translational medicine strategy
is to progress rapidly to first-in-human studies once it has
established the pharmacokinetics, pharmacodynamic, safety, and
manufacturability of the product candidate in preclinical studies.
For more information, please visit www.miragen.com.
For information on clinical trials please visit
www.clinicaltrials.gov.
Investor/Media
Contact:
Adam
Levy
Chief Business
Officer
(720)
407-4595
alevy@miragen.com
Miragen Therapeutics (NASDAQ:MGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Miragen Therapeutics (NASDAQ:MGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Miragen Therapeutics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de